Helsinn and Johnson & Johnson returned to add $21m in extra funding to the $44m series B round the surgical marker developer closed in 2018.
On Target Laboratories, a US-based developer of marking technology for cancer surgery, raised $21m in additional series B funding from investors including pharmaceutical firms Helsinn and Johnson & Johnson yesterday.
The corporates invested through respective subsidiaries 3B Future Health Fund and Johnson & Johnson Innovation – JJDC respectively, and were joined by HIG Capital, Elevate Ventures and The Hurvis Group.
Founded in 2010 as a Purdue University spinout, On Target is working on fluorescent markers designed to locate and illuminate…
